Octagon Capital Advisors »

Dianthus Therapeutics shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $45M 1.7M 25.88
2024-03-31 $41M 1.4M 30.00
2023-12-31 $5.8M 554k 10.40
2023-09-30 $6.6M 480k 13.67

More positions owned by Octagon Capital Advisors

Apellis Pharmaceuticals Call Option (APLS)
Insmed Com Par $.01 Call Option (INSM)
Dianthus Therapeutics (DNTH)
Structure Therapeutics Sponsored Ads (GPCR)
Dyne Therapeutics (DYN)
Arrivent Biopharma (AVBP)
Verona Pharma Sponsored Ads (VRNA)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Bridgebio Pharma (BBIO)
Ocular Therapeutix (OCUL)
Perspective Therapeutics Com New (CATX)
Mind Medicine Mindmed Com New (MNMD)
Praxis Precision Medicines I Com New (PRAX)
Taysha Gene Therapies Com Shs (TSHA)

View all positions for Octagon Capital Advisors

Top funds holding Dianthus Therapeutics

Bain Capital Life Sciences Investors
Avidity Partners Management
Fairmount Funds Management
RA Capital Management
VR Adviser
Octagon Capital Advisors
BlackRock
Vanguard Group
5AM Venture Management
Dr. Jeffrey R. Jay, M.D.
Henderson Group
Vestal Point Capital
Geode Capital Management
State Street Corporation
Braidwell

View all funds holding Dianthus Therapeutics